Literature DB >> 19391150

Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil.

Philip Seeman1, Hong-Chang Guan, Hélène Hirbec.   

Abstract

Although it is commonly stated that phencyclidine is an antagonist at ionotropic glutamate receptors, there has been little measure of its potency on other receptors in brain tissue. Although we previously reported that phencyclidine stimulated cloned-dopamine D2Long and D2Short receptors, others reported that phencyclidine did not stimulate D2 receptors in homogenates of rat brain striatum. This study, therefore, examined whether phencyclidine and other hallucinogens and psychostimulants could stimulate the incorporation of [(35)S]GTP-gamma-S into D2 receptors in homogenates of rat brain striatum, using the same conditions as previously used to study the cloned D2 receptors. Using 10 microM dopamine to define 100% stimulation, phencyclidine elicited a maximum incorporation of 46% in rat striata, with a half-maximum concentration of 70 nM for phencyclidine, when compared with 80 nM for dopamine, 89 nM for salvinorin A (48 nM for D2Long), 105 nM for lysergic acid diethylamide (LSD), 120 nM for R-modafinil, 710 nM for dizocilpine, 1030 nM for ketamine, and >10,000 nM for S-modafinil. These compounds also inhibited the binding of the D2-selective ligand [(3)H]domperidone. The incorporation was inhibited by the presence of 200 microM guanylylimidodiphosphate and also by D2 blockade, using 10 microM S-sulpiride, but not by D1 blockade with 10 microM SCH23390. Hypertonic buffer containing 150 mM NaCl inhibited the stimulation by phencyclidine, which may explain negative results by others. It is concluded that phencyclidine and other psychostimulants and hallucinogens can stimulate dopamine D2 receptors at concentrations related to their behavioral actions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19391150     DOI: 10.1002/syn.20647

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  29 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

Review 2.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

Review 3.  Is schizophrenia a dopamine supersensitivity psychotic reaction?

Authors:  Mary V Seeman; Philip Seeman
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-10-12       Impact factor: 5.067

Review 4.  Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.

Authors:  Maria R Dauvermann; Graham Lee; Neil Dawson
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

5.  Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.

Authors:  Xiaomeng Xu; Shifan Ma; Zhiwei Feng; Guanxing Hu; Lirong Wang; Xiang-Qun Xie
Journal:  J Mol Graph Model       Date:  2016-08-08       Impact factor: 2.518

Review 6.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

7.  Common variants in DRD2 are associated with sleep duration: the CARe consortium.

Authors:  Brian E Cade; Daniel J Gottlieb; Diane S Lauderdale; David A Bennett; Aron S Buchman; Sarah G Buxbaum; Philip L De Jager; Daniel S Evans; Tibor Fülöp; Sina A Gharib; W Craig Johnson; Hyun Kim; Emma K Larkin; Seung Ku Lee; Andrew S Lim; Naresh M Punjabi; Chol Shin; Katie L Stone; Gregory J Tranah; Jia Weng; Kristine Yaffe; Phyllis C Zee; Sanjay R Patel; Xiaofeng Zhu; Susan Redline; Richa Saxena
Journal:  Hum Mol Genet       Date:  2015-10-13       Impact factor: 6.150

Review 8.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

9.  Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat.

Authors:  Veronica Serra; Liana Fattore; Maria Scherma; Roberto Collu; Maria Sabrina Spano; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

Review 10.  Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.

Authors:  Nikhil Neelkantan; Alina Mikhaylova; Adam Michael Stewart; Raymond Arnold; Visar Gjeloshi; Divya Kondaveeti; Manoj K Poudel; Allan V Kalueff
Journal:  ACS Chem Neurosci       Date:  2013-08-06       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.